372504-89-7

Upstream product

• 40217-17-2 (R)-4-(phenylmethyl)-2-oxazolidinone 

Downstream Products

• 128057-11-4 (R)-4-Benzyl-3-(6-benzyloxymethoxy-2-ethyl-hexanoyl)-oxazolidin-2-one 
• 178744-36-0 (R)-4-Benzyl-3-[2-(3,5-diisopropoxy-4-methoxy-phenyl)-acetyl]-oxazolidin-2-one 
• 221292-89-3 (R)-4-Benzyl-3-((S)-4-methyl-hexanoyl)-oxazolidin-2-one 
• 334009-84-6 (R)-4-benzyl-3-[4-(2-methyl-1,3-dioxolan-2-yl)butyryl]oxazolidin-2-one 
• 301659-87-0 (R)-4-Benzyl-3-((E)-3-naphthalen-2-yl-acryloyl)-oxazolidin-2-one 
• 220041-95-2 (R)-4-benzyl-3-(2-p-tolylethanoyl)oxazolidin-2-one 
• 656833-57-7 (4R)-4-benzyl-3-(5-methylhexanoyl)-1,3-oxazolidin-2-one 
• 928842-48-2 (R)-4-benzyl-3-[(R)-8-(tert-butyldiphenylsilyloxy)-6-(methoxymethoxy)octanoyl]-2-oxazolidinone 
• 934219-81-5 (R)-4-benzyl-3-[(4S,5S)-5-(3,4-dimethoxyphenyl)-5-(triisopropylsilyloxy)-4-(trityloxymethyl)pentanoyl]-2-oxazolidinone 
• 934220-00-5 (R)-4-benzyl-3-[(4R,5R)-5-(3,4-dimethoxyphenyl)-5-(triisopropylsilyloxy)-4-(trityloxymethyl)pentanoyl]-2-oxazolidinone 
• 344597-00-8 (R)-4-benzyl-3-(hex-5′-enoyl)oxazolidin-2-one 
• 1054529-60-0 (R)-4-benzyl-3-pent-2-enoyl-oxazolidin-2-one 
• 1173420-46-6 (R)-4-benzyl-3-(but-3-enoyl)oxazolidin-2-one 

Relevant academic research and scientific papers

A new, ring closing metathesis-based synthesis of (-)-fumagillol

(Equation presented) A new strategy to access the fumagillin/fumagillol skeleton is proposed. An Evans aldolization and a RCM involving an enone are used for the preparation of a key cyclohexanone intermediate, which was readily converted to fumagillol. The synthesis also features an efficient preparation of isogeraniol and isogeranic acid.

Syntheses of all the stereoisomers of butanol type 1,7-seco-2,7′-cyclolignane

All the stereoisomers of butanol type 1,7-seco-2,7′-cyclolignane were stereoselectively synthesized by employing (S)- and (R)-Evans' auxiliaries to construct the stereochemistry. (+)- and (-)-Kadangustin J and their diastereomers were also prepared. The optical purity of the synthesized butanol type 1,7-seco-2,7′-cyclolignane was more than 99%ee.

GAMMA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, W, X, and n are defined herein, which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

3-Amino-2-hydroxyalkanoic acids and their prodrugs

Compounds having the formula are useful for treating conditions which arise from or are exacerbated by angiogenesis. Also disclosed are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting a